MedPath

PIERRE FABRE MEDICAMENT

🇮🇳India
Ownership
-
Employees
-
Market Cap
-
Website

Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer

Phase 3
Completed
Conditions
Recurrent or Metastatic Head and Neck Carcinoma
Interventions
First Posted Date
2015-01-27
Last Posted Date
2019-03-05
Lead Sponsor
Pierre Fabre Medicament
Target Recruit Count
459
Registration Number
NCT02347332
Locations
🇫🇷

Institut de Recherche Pierre Fabre, Toulouse, France

Effect of F2695 on Brain Activity Measured by Functional Magnetic Resonance Imaging

Phase 1
Completed
Conditions
Subject
Interventions
Drug: Placebo
First Posted Date
2014-10-17
Last Posted Date
2016-10-13
Lead Sponsor
Pierre Fabre Medicament
Target Recruit Count
17
Registration Number
NCT02266966
Locations
🇫🇷

Centre d'Investigation Clinique (CIC), Toulouse, France

F17464 in Acute Schizophrenia Trial

Phase 2
Completed
Conditions
Schizophrenia
Interventions
Drug: Placebo
First Posted Date
2014-05-30
Last Posted Date
2016-12-16
Lead Sponsor
Pierre Fabre Medicament
Target Recruit Count
158
Registration Number
NCT02151656

PERmixon® in LUTS Evaluation Study (PERLES)

Phase 4
Completed
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Drug: Permixon® 160 mg
Drug: Placebo matching Permixon® 160 mg
First Posted Date
2014-04-23
Last Posted Date
2016-09-02
Lead Sponsor
Pierre Fabre Medicament
Target Recruit Count
833
Registration Number
NCT02121613

Nicotine Patch - Bioequivalence Study

Phase 1
Completed
Conditions
Healthy Smokers
First Posted Date
2014-03-17
Last Posted Date
2014-06-12
Lead Sponsor
Pierre Fabre Medicament
Target Recruit Count
74
Registration Number
NCT02089308

A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast Cancer

Phase 3
Terminated
Conditions
Advanced Breast Cancer
Interventions
Drug: Vinflunine+Gemcitabine
Drug: Paclitaxel+Gemcitabine
First Posted Date
2014-02-04
Last Posted Date
2019-08-28
Lead Sponsor
Pierre Fabre Medicament
Target Recruit Count
1004
Registration Number
NCT02054338

Efficacy and Safety of V0111 Cream on Open Cracked Heel in Diabetic Patients With Polyneuropathy.

Not Applicable
Completed
Conditions
Open Cracked Heel in Diabetic Patients With Polyneuropathy
Interventions
Device: Placebo
First Posted Date
2014-01-24
Last Posted Date
2015-04-27
Lead Sponsor
Pierre Fabre Medicament
Target Recruit Count
193
Registration Number
NCT02045199

Exploratory Study in the Relief of Drug-induced Xerostomia Associated With Hyposialia

Not Applicable
Completed
Conditions
Drug-induced Xerostomia
First Posted Date
2013-12-09
Last Posted Date
2014-04-15
Lead Sponsor
Pierre Fabre Medicament
Target Recruit Count
40
Registration Number
NCT02005328

Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

Phase 3
Completed
Conditions
Malignant Neoplasm of Breast
Interventions
First Posted Date
2013-09-30
Last Posted Date
2019-05-02
Lead Sponsor
Pierre Fabre Medicament
Target Recruit Count
112
Registration Number
NCT01953003
Locations
🇸🇬

Gleneagles Hospital, Singapore, Singapore

🇸🇬

NUH, Singapore, Singapore

Bronchodilator Properties and Safety in Asthma

Phase 2
Completed
Conditions
Asthma
Interventions
Other: Placebo
First Posted Date
2013-09-26
Last Posted Date
2014-09-17
Lead Sponsor
Pierre Fabre Medicament
Target Recruit Count
59
Registration Number
NCT01951222
Locations
🇩🇪

CRO, Gauting, Germany

© Copyright 2025. All Rights Reserved by MedPath